UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 96

Sortiert nach

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Clinical cancer research, 2007-09, Vol.13 (18), p.5549s-5555s

2007

Link zum Volltext

Verfügbarkeit prüfen

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Clinical cancer research, 2010-03, Vol.16 (6), p.1915-1923

2010

Link zum Volltext

Verfügbarkeit prüfen

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2015

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Link zum Volltext

Verfügbarkeit prüfen

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

Clinical breast cancer, 2003-06, Vol.4 (2), p.126-137

2003

Link zum Volltext

Verfügbarkeit prüfen

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Investigational new drugs, 2007-08, Vol.25 (4), p.359-367

2007

Link zum Volltext

Verfügbarkeit prüfen

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Molecular cancer therapeutics, 2002-07, Vol.1 (9), p.747-758

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-12, Vol.12 (24), p.7406-7413

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

Clinical cancer research, 2007-06, Vol.13 (11), p.3293-3301

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinical experience with monoclonal antibodies to epidermal growth factor receptor

Current oncology reports, 2005-03, Vol.7 (2), p.96-103

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus

Cancer research (Chicago, Ill.), 2021-11, Vol.81 (22_Supplement), p.PO-018-PO-018

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks

Cancer research (Chicago, Ill.), 1994-01, Vol.54 (2), p.427-436

1994

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2589-2589

2017

Link zum Volltext

Verfügbarkeit prüfen

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Blood, 2014-12, Vol.124 (21), p.4500-4500

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4507: SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4507-4507

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

Clinical cancer research, 2002-01, Vol.8 (1), p.75

2002

Link zum Volltext

Verfügbarkeit prüfen

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

Current oncology reports, 2005-04, Vol.7 (2), p.123-128

2005

Link zum Volltext

Verfügbarkeit prüfen

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

Clinical lung cancer, 2004-12, Vol.6 Suppl 1, p.S35-S42

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

Investigational new drugs, 2007-08, Vol.25 (4), p.357-357

2007

Link zum Volltext

Verfügbarkeit prüfen

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol

Cancer research (Chicago, Ill.), 1988-07, Vol.48 (14), p.4093-4100

1988

Link zum Volltext

Verfügbarkeit prüfen

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Blood, 2013-11, Vol.122 (21), p.4104-4104

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT146-CT146

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3504-3504

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 96

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(96)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Antineoplastic Agents
(20)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Pharmacology. Drug Treatments
(18)
Female
(17)
Adult
(13)
Aged
(13)
Middle Aged
(13)
Male
(12)
Chemotherapy
(11)
Neoplasms - Drug Therapy
(11)
Antineoplastic Agents - Therapeutic Use
(8)
Oncology
(8)
Cancer
(7)
Drug Administration Schedule
(6)
Neutropenia - Chemically Induced
(6)
Tumors
(6)
Animals
(5)
Antineoplastic Agents - Pharmacology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Paclitaxel (Taxol)

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

Clinical experience with monoclonal antibodies to epidermal growth factor receptor

Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Abstract 4507: SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts

Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors

Aktive Filter

Suchergebnisse filtern